Although cancer is highly heterogeneous, all metastatic cancer is considered American Joint Committee on Cancer (AJCC) Stage IV disease. The purpose of this project was to redefine staging of metastatic cancer. Internal validation of nationally representative patient data from the National Cancer Database (n = 461 357; 2010-2013), and external validation using the Surveillance, Epidemiology and End Results database (n = 106 595; 2014-2015) were assessed using the concordance index for evaluation of survival prediction. A Cox proportional hazards model was used for overall survival by considering identified phenotypes (latent classes) and other confounding variables. Latent class analysis was performed for phenotype identification, where Bayesian information criterion (BIC) and sample-size-adjusted BIC were used to select the optimal number of distinct clusters. Kappa coefficients assessed external cluster validation. Latent class analysis identified five metastatic phenotypes with differences in overall survival (P
CITATION STYLE
Zaorsky, N. G., Wang, X., Garrett, S. M., Lehrer, E. J., Lin, C., DeGraff, D. J., … Wang, M. (2022). Pan-cancer analysis of prognostic metastatic phenotypes. International Journal of Cancer, 150(1), 132–141. https://doi.org/10.1002/ijc.33744
Mendeley helps you to discover research relevant for your work.